Helicon has identified Emergency Medicine, General and Cosmetic Surgery and Oncology markets as high potential segments in China and is seeking products with a strategic fit to the existing portfolio. More
APR is interested to in-license new early stage, innovative and patent protected products/technologies (preferably off patent or close to expiry) for oral, topical or transdermal administration More
TPU is constantly seeking to acquire products/technologies that complement the company's pipeline. And for companies looking for a product-life-cycle extension or a new drug delivery system, Teikoku Pharma is the strategic partner of choice. More